Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson

Last Updated: February 9, 2023

Details for Patent: 7,699,609

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,699,609 protect, and when does it expire?

Patent 7,699,609 protects ARESTIN and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 7,699,609
Title:Dispensing apparatus and cartridge with deformable tip
Abstract: A device for the treatment of periodontal disease. The device includes a handle that has a configuration familiar to dental professionals and a cartridge that is locked into the handle when use, typically delivery of a composition to a periodontal pocket, is desired. The cartridge provides for effective delivery of compositions, such as agents, as its tip is deformable, typically from a circular to an oval shape so as to flatten. The deformation may be made either manually, by the dental professional, or upon contact with teeth or other tissues, whereby this flattened tip can penetrate deeply into periodontal pockets for quick and direct application of the composition, for example, therapeutic agents.
Inventor(s): Lawter; James R. (Yardley, PA), Lanzilotti; Michael G. (Newtown, PA), Bates; Mark (Westwood, MA), Hunter; Gregory H. (Dover, MA)
Assignee: Orapharma, Inc. (Warminster, PA)
Application Number:10/763,632
Patent Claim Types:
see list of patent claims
Device; Use;

Drugs Protected by US Patent 7,699,609

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Orapharma ARESTIN minocycline hydrochloride POWDER, EXTENDED RELEASE;DENTAL 050781-001 Feb 16, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,699,609

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039205 See Plans and Pricing
Australia 2003223384 See Plans and Pricing
Australia 2009201777 See Plans and Pricing
Brazil 0308859 See Plans and Pricing
Canada 2479995 See Plans and Pricing
Colombia 5611079 See Plans and Pricing
Cyprus 1114425 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.